HALO 8-K 2026-11-05

HALOZYME THERAPEUTICS, INC. (HALO) 8-K dated 2026-11-05 — accession 0001159036-26-000143.

HALOZYME THERAPEUTICS, INC. (HALO) is a biotechnology company listed on US.

HALOZYME THERAPEUTICS, INC. filed a 8-K on 2026-11-05. Accession 0001159036-26-000143.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported HALO revenue for 2025-12-31 was $1.40B. Net income was $316.9M. Revenue was up 37.6% from 2024-12-31 to 2025-12-31. HALO currently screens at market cap $7.10B.

Not investment advice. The HALO SEC hub lists recent forms. The stock page is the research view.